Introduction
============

Bladder cancer may be classified into two stages: Non-muscle-invasive disease of low grade, and progressive muscle-invasive disease of high grade, which may further deteriorate into metastatic cancer ([@b1-ol-0-0-5819]). This type of cancer predominantly occurs as urothelial cell carcinoma and ranks as the fourth most common malignancy and the eighth most common cause of cancer-associated mortality in men ([@b2-ol-0-0-5819]). Overexpressed or mutant fibroblast growth factor receptor 3 (*FGFR3*) may contribute to the development of the transformed phenotype of urothelial carcinoma ([@b3-ol-0-0-5819]), and the targeted inhibition of *FGFR3* may thus prevent the development of superficial bladder cancer ([@b4-ol-0-0-5819]). The transcription factor nuclear factor κB (NFκB) is an important mediator of the angiogenesis and metastasis of bladder cancer ([@b5-ol-0-0-5819]). Activating mutations in *FGFR3* can promote NFκB transcriptional activity through the important mediator transforming growth factor-β-activated kinase 1 (*TAK1*), which exerts a positive regulatory effect on the activity of NFκB in urothelial cell carcinoma ([@b6-ol-0-0-5819]). However, the exact regulatory effect of *TAK1* on the progression of bladder cancer remains unclear.

RNA interference may effectively aid in defining the roles of specific genes in the progression of cancer when specifically designed siRNAs are used to silence target genes ([@b7-ol-0-0-5819],[@b8-ol-0-0-5819]). Using the microarray expression data of bladder cancer cells transfected with control siRNA or *TAK1*-specific siRNA which were deposited by Salazar *et al* ([@b6-ol-0-0-5819]), the present study aimed to identify the differentially expressed genes (DEGs) and to screen for tumor-associated DEGs, followed by identification of the biological processes or pathways implicated by DEGs and the hub nodes in the complex protein-protein interaction (PPI) network and sub-network, in an attempt to provide a deeper insight into the molecular mechanisms mediating the effect of silencing *TAK1* on bladder cancer.

Materials and methods
=====================

### Gene expression profiles

The gene expression profiles (accession number GSE52452) ([@b6-ol-0-0-5819]) from 6 samples of MGHU3 (Y375C) mutant *FGFR3* bladder cancer cells that were transfected with control siRNA (GSM1267159-61) or TAK1-specific siRNA (GSM1267150-52), were downloaded from the public functional genomics data repository of Gene Expression Omnibus ([@b9-ol-0-0-5819]). These 6 samples (3 control samples vs. 3 *TAK1* siRNA-treated samples) were previously researched using Affymetrix Human Gene 1.0 ST Array.

### Data processing and screening of DEGs

The raw expression data were processed through RMA background correction ([@b10-ol-0-0-5819]), quantile normalization, log base 2 (log~2~) transformation and probeset summarization to obtain the gene expression matrix by employing Affy package in Bioconductor ([@b11-ol-0-0-5819]) and probe annotation files provided by Brain Array Lab ([brainarray.mbni.med.umich.edu/](brainarray.mbni.med.umich.edu/)). Subsequently, the lists of DEGs between control and *TAK1*-specific siRNA-treated cells were generated under the thresholds of \|log~2~ fold change (FC)\|≥1 (fold-change magnitude, \>2) and P-value \<0.05 using the empirical Bayes method offered by Limma package ([@b12-ol-0-0-5819]).

### Functional enrichment analysis of DEGs

To provide insight into the biological functions or pathways involving the identified DEGs, the Gene Ontology (GO) Biological Process ([@b13-ol-0-0-5819]) and Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b14-ol-0-0-5819]) pathway enrichment analyses of DEGs were performed with the criterion of P\<0.05 using the Database for Annotation, Visualization and Integrated Discovery ([@b15-ol-0-0-5819]).

### Functional annotations of DEGs

To identify the specific functions of DEGs, transcription factors were screened from the DEGs based on the TRANSFAC database ([@b16-ol-0-0-5819]), accompanied by screening of tumor-suppressor genes (TSGs) using the TSGene ([@b17-ol-0-0-5819]) database and identification of oncogenic genes using the tumor-associated genes (TAG) database ([@b18-ol-0-0-5819]).

### Construction of PPI network and screening of sub-network

In consideration of the gene-gene interactions in the complex biological systems, the identified DEGs were inputted into the Search Tool for the Retrieval of Interacting Genes (STRING) database ([@b19-ol-0-0-5819]) to identify the interacting pairs with a combined score \>0.9 (data downloaded on May 9, 2014). The PPI network was constructed using Cytoscape software ([@b20-ol-0-0-5819]), followed by excavation of the sub-network using the BioNet tool (bionet.bioapps.biozentrum.uni-wuerzburg.de/). KEGG pathway enrichment analysis of DEGs in the sub-network was performed to identify the associated biological pathways.

Results
=======

### Screened DEGs

With the criteria of \|log~2~ FC\|≥1 and P\<0.05, a total of 43 downregulated genes and 21 upregulated genes were identified in the mutant *FGFR3* bladder cancer cells transfected with *TAK1*-specific siRNA in comparison with the cells transfected with control siRNA.

### Functional enrichment results of DEGs

By performing a KEGG pathway enrichment analysis of the separate upregulated and downregulated genes, it was demonstrated that the downregulated genes were significantly enriched in five pathways, including the NOD-like receptor signaling pathway \[P=0.014731; mitogen-activated protein kinase kinase kinase 7 (*MAP3K7*) and tumor necrosis factor α-induced protein 3 (*TNFAIP3*)\] and the upregulated genes were enriched in the cytokine-cytokine receptor interaction pathway \[P=0.018547; epidermal growth factor receptor (*EGFR*) and interleukin 18 (*IL18*)\] ([Table I](#tI-ol-0-0-5819){ref-type="table"}). The GO Biological Process enrichment analysis revealed that the downregulated genes were associated with cellular responses, including regulation of catalytic activity \[P=5.45×10^−4^; e.g. aldehyde dehydrogenase 1 family member A1 (*ALDH1A1*), β-arrestin (*ARRB1*), inositol trisphosphate receptor (*ITPR1*) and *MAP3K7*)\] and cellular response to chemical stimulus \[P=1.38×10^−3^; e.g. *ALDH1A1*, *ARRB1*, *ITPR1*, *MAP3K7*, cytochrome P450 family 3 subfamily A polypeptide 5 (*CYP3A5*) and glutathione S-transferase α1 (*GSTA1*)\]; the upregulated genes were associated with cellular developmental processes \[P=5.80×10^−4^; e.g. *EGFR*, early growth response 1 (*EGR1*) and parathyroid hormone-like hormone (*PTHLH*)\] ([Table II](#tII-ol-0-0-5819){ref-type="table"}).

### Results of functional annotation of DEGs

Using TRANSFAC, TSGene and TAG databases, the functional annotation analysis screened 1 transcription factor (upregulated *EGR1*) and 9 TAGs, including 1 oncogene (upregulated *EGFR*), 5 TSGs (downregulated *TNFAIP3*, ras association domain family member 5 and carcinoembryonic antigen related cell adhesion molecule 7; upregulated GLI pathogenesis related 1 and *EGR1*) and 3 other TAGs (downregulated breast carcinoma amplified sequence 1 and activin membrane-bound inhibitor; upregulated *PTHLH*).

### Analysis of the PPI network

Using the STRING database and Cytoscape tool, a PPI analysis of the DEGs was performed and an integrated PPI network was obtained. Based on this network, the top 10 hub nodes representing important roles in the complex metabolic networks were *EGFR* (degree, 178), *CYP3A5* (degree, 83), *MAP3K7* (degree, 58), *GSTA1* (degree, 56), *PTHLH* (degree, 47), *ALDH1A1* (degree, 45), potassium voltage-gated channel subfamily D member 2 (degree, 43), *EGR1* (degree, 42), *ARRB1* (degree, 36) and *ITPR1* (degree, 33) ([Fig. 1](#f1-ol-0-0-5819){ref-type="fig"}). Additionally, this network revealed a correlation of *MAP3K7* with *TNFAIP3*.

### Analysis of the screened sub-network

Using the BioNet tool, a sub-network with *EGFR* at the core was screened from the PPI network, in which *EGFR* was associated with v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (*ERBB2*), growth factor receptor-bound protein 2 (*GRB2*) and phosphoinositide-3-kinase, regulatory subunit 1 (*PIK3R1*) ([Fig. 2](#f2-ol-0-0-5819){ref-type="fig"}). Furthermore, the DEGs in the sub-network were found to be enriched in various pathways associated with cancer, including the *ErbB* signaling pathway (P=3.07×10^−7^; e.g. *EGFR*, *ERBB2*, *GRB2* and *PIK3R1*), pathways in cancer (P=5.90×10^−7^; e.g. *EGFR*, *ERBB2*, *GRB2* and *PIK3R1*), prostate cancer (P=1.04×10^−4^; e.g. *EGFR*, *ERBB2*, *GRB2* and *PIK3R1*), endometrial cancer (P=1.64×10^−4^; *EGFR*, *ERBB2*, *GRB2* and *PIK3R1*), non-small cell lung cancer (P=1.90×10^−4^; *EGFR*, *ERBB2*, *GRB2* and *PIK3R1*) and glioma (P=3.90×10^−4^; e.g. *EGFR*, *GRB2* and *PIK3R1*) ([Table III](#tIII-ol-0-0-5819){ref-type="table"}).

Discussion
==========

By re-analyzing the microarray data from specific mutant *FGFR3* bladder cancer cells using bioinformatic methods, the present study identified 64 genes with significantly altered expression between *TAK1*-specific siRNA-treated cells and the control siRNA-treated cells, including 9 TAGs. The downregulated genes were related to the NOD-like receptor signaling pathway and cellular response functions, whereas the upregulated genes were associated with cellular developmental processes. By constructing a PPI network, the present study identified 10 hub nodes that may exert the predominant effects on the network. Furthermore, the DEGs in the sub-network with *EGFR* at the core were associated with various types of cancer and the *ErbB* signaling pathway.

*TAK1* siRNA vs. control siRNA samples yielded 43 downregulated genes, of which 6 were identified to be hub nodes in the PPI network, including *CYP3A5*, *MAP3K7*, *GSTA1*, *ALDH1A1*, *ARRB1* and *ITPR1*. *CYP3A5* and *GSTA1* are associated with the detoxification of chemical stimuli, electrophilic compounds or other damage stimuli ([@b21-ol-0-0-5819],[@b22-ol-0-0-5819]). They were also enriched in the term metabolism of xenobiotics by cytochrome P450, which plays important roles in detoxification ([@b23-ol-0-0-5819]). *MAP3K7*, which correlated with *TNFAIP3*, was enriched in the NOD-like receptor signaling pathway which is involved in sensing intracellular microbial motifs or other damage stimuli ([@b24-ol-0-0-5819]). *ALDH1A1* and *CYP3A5* were enriched in retinol metabolism; the loss of retinol acyltransferase is inversely correlated with the invasion bladder cancer ([@b25-ol-0-0-5819]). *ARRB1* is considered to cause a specific dampening cellular response to stimuli or sensory signals ([@b26-ol-0-0-5819]) and *ITPR1* mediates calcium release which then amplifies apoptosis in response to specific stimuli ([@b27-ol-0-0-5819],[@b28-ol-0-0-5819]). Accordingly, the present study further demonstrated that the 6 hub nodes in the PPI network were enriched in the GO function cellular response to chemical stimulus. It is therefore possible that silencing of *TAK1* using specific siRNA transfection may alter the cellular response-associated pathways or functions in response to stimuli via regulating the expression of the 6 DEGs.

*TAK1* siRNA treatment induced 21 upregulated genes in bladder cancer cells, among which *EGFR*, *PTHLH* and *EGR1* were identified as hub nodes in the PPI network. These 3 genes were all enriched in cellular developmental processes. As exemplified, activated *EGFR*, which contributes to phenotypic characteristics in various tumor types ([@b29-ol-0-0-5819]), is an effective therapeutic target for the treatment of bladder cancer ([@b30-ol-0-0-5819],[@b31-ol-0-0-5819]). Increased expression of *PTHLH* resulting from downregulated *p38MAPK* signaling is associated with metastatic lesions to the liver and lung from colon cancer cells ([@b32-ol-0-0-5819]). *EGR1* also exerts pro-tumorigenic effects by contributing to tumor infiltration, node formation and metastasis ([@b33-ol-0-0-5819]). Thus, the upregulation of these genes in *TAK1* siRNA-treated bladder cancer cells may suggest that silencing *TAK1* has the effect of promoting cancer cell developmental processes. Furthermore, the present study also predicted *EGFR*, *EGR1* and *PTHLH* as TAGs, which suggests their potential use as therapeutic targets for the diagnosis and treatment of bladder cancer.

Using BioNet software, a sub-network with *EGFR* at the core was screened from the PPI network. According to the PPI network, *EGFR* was correlated with *ERBB2*, *GRB2* and *PIK3R1*. These 4 DEGs were enriched in various cancer types, including prostate cancer, endometrial cancer, non-small cell lung cancer and glioma. As previously reported, the *EGFR* family of four receptors including *EGFR* and *ERBB2*, is implicated in the development and progression of various human cancer types ([@b34-ol-0-0-5819]). The activation of *ERBB2* may result in resistance to cetuximab-based therapy targeting *EGFR*, while the inhibition of this gene can restore cetuximab sensitivity in patients with cetuximab-resistant cancers ([@b35-ol-0-0-5819]). *GRB2* amplification is observed in esophageal squamous cell carcinoma and is significantly involved in lymph node metastases ([@b36-ol-0-0-5819]). Phosphatidylinositol 3-kinase (*PI3K*), which may promote cancer cell survival, is an important therapeutic target in cancer ([@b37-ol-0-0-5819]). *PIK3R1*, the inhibitory subunit of *PI3K*, often undergoes mutations in endometrial cancer ([@b38-ol-0-0-5819],[@b39-ol-0-0-5819]). The enrichment results also revealed the these 4 DEGs were enriched in *ErbB* signaling pathway, which is involved in regulating cell survival and adhesion ([@b40-ol-0-0-5819]). Silencing *TAK1* in bladder cancer cells led to the upregulation of *EGFR* and downregulation of *ERBB2*, *GRB2* and *PIK3R1*, suggesting an inhibitory effect of silencing *TAK1* on the metastasis of bladder cancer cells via modulation of the *ErbB* signaling pathway. However, the explicit molecular mechanisms require further research.

In summary, the present study demonstrated that silencing *TAK1* induced 43 downregulated and 21 upregulated genes. Silencing *TAK1* may lead to decreased cellular response to chemical stimuli via downregulating *CYP3A5*, *MAP3K7*, *GSTA1*, *ALDH1A1*, *ARRB1* and *ITPR1*, as well as increased cancer cell developmental processes via upregulating *EGFR*, *EGR1* and *PTHLH*. In addition, silencing *TAK1* may exert regulatory effects on bladder cancer metastasis and other various cancer types via regulating the expression of *EGFR*, *ERBB2*, *GRB2* and *PIK3R1*.

The present study was supported by the Zhejiang Provincial Natural Science Foundation (grant no., LY13H050001).
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###### 

Significantly enriched KEGG pathways of upregulated and downregulated genes.

  KEGG pathway                                     P-value     Gene list
  ------------------------------------------------ ----------- -----------------
  Downregulated genes                                          
    Aldosterone-regulated sodium reabsorption      0.0079126   SCNN1G, SGK1
    NOD-like receptor signaling pathway            0.014731    MAP3K7, TNFAIP3
    Retinol metabolism                             0.0177602   ALDH1A1, CYP3A5
    Metabolism of xenobiotics by cytochrome P450   0.0215999   CYP3A5, GSTA1
    Drug metabolism-cytochrome P450                0.0227555   CYP3A5, GSTA1
  Upregulated genes                                            
    Cytokine-cytokine receptor interaction         0.018547    EGFR, IL18

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Top 10 significantly enriched GO terms of upregulated and downregulated genes.

  GO term                                                        P-value    Gene list
  -------------------------------------------------------------- ---------- -----------------------------------------------------------------------------------------
  Downregulated genes                                                       
    GO:0006805 xenobiotic metabolic process                      5.32E-04   ACSL1, ALDH1A1, CYP3A5, GSTA1
    GO:0050790 regulation of catalytic activity                  5.45E-04   ACER2, ACSL1, ALDH1A1, ARRB1, DUSP10, FGD3, ITPR1, MAP3K7, SGK1, SYTL2, TNFAIP3
    GO:0071466 cellular response to xenobiotic stimulus          5.45E-04   ACSL1, ALDH1A1, CYP3A5, GSTA1
    GO:0009410 response to xenobiotic stimulus                   5.85E-04   ACSL1, ALDH1A1, CYP3A5, GSTA1
    GO:0045824 negative regulation of innate immune response     5.89E-04   DUSP10, TNFAIP3
    GO:0032715 negative regulation of interleukin-6 production   9.53E-04   ARRB1, TNFAIP3
    GO:0065009 regulation of molecular function                  1.07E-03   ACER2, ACSL1, ALDH1A1, ARRB1, BAMBI, DUSP10, FGD3, ITPR1, MAP3K7, SGK1, SYTL2, TNFAIP3
    GO:0070887 cellular response to chemical stimulus            1.38E-03   ACER2, ACSL1, ALDH1A1, ARRB1, BAMBI, CYP3A5, FGD3, GDF15, GSTA1, ITPR1, MAP3K7, TNFAIP3
    GO:0002819 regulation of adaptive immune response            2.02E-03   DUSP10, MAP3K7, TNFAIP3
    GO:0018149 peptide cross-linking                             2.08E-03   SPRR1A, SPRR3
  Upregulated genes                                                         
    GO:0036296 response to increased oxygen levels               1.01E-06   EGR1, IL18, PDPN
    GO:0055093 response to hyperoxia                             1.01E-06   EGR1, IL18, PDPN
    GO:0030324 lung development                                  2.45E-05   HEG1, IL18, PDPN, PTHLH
    GO:0030323 respiratory tube development                      2.64E-05   HEG1, IL18, PDPN, PTHLH
    GO:0060541 respiratory system development                    4.12E-05   HEG1, IL18, PDPN, PTHLH
    GO:0001945 lymph vessel development                          2.81E-04   HEG1, PDPN
    GO:0060571 morphogenesis of an epithelial fold               4.59E-04   EGFR, PTHLH
    GO:0048869 cellular developmental process                    5.80E-04   ANTXR1, EGFR, EGR1, HEG1, IL18, MDK, MEA1, PDPN, PTHLH, STRADB
    GO:0009725 response to hormone stimulus                      6.92E-04   EGFR, EGR1, IL18, MDK, STRADB
    GO:0071320 cellular response to cAMP                         7.60E-04   EGR1, IL18

GO, Gene Ontology.

###### 

Top 10 significantly enriched KEGG pathways of differentially expressed genes in the sub-network.

  KEGG pathway                 P-value    Gene list
  ---------------------------- ---------- --------------------------------------------------------------------------------
  ErbB signaling pathway       3.07E-07   EGFR, ERBB2, GRB2, NRG1, HBEGF, ERBB3, PIK3R1, EGFR, ITGA6, PTGS2, JUP, IGF1R,
  Pathways in cancer           5.90E-07   MET, FOS, IL8, ERBB2, GRB2, PIK3R1
  Focal adhesion               7.34E-07   EGFR, ITGA6, CAV1, IGF1R, MET, VAV2, ERBB2, GRB2, PIK3R1
  Hepatitis C                  5.77E-06   EGFR, STAT2, IRF1, IL8, GRB2, OAS1, PIK3R1
  Endocytosis                  8.07E-05   EGFR, ARRB1, AP2M1, CAV1, IGF1R, MET, ERBB3
  Prostate cancer              1.04E-04   EGFR, IGF1R, ERBB2, GRB2, PIK3R1,
  Malaria                      1.52E-04   MET, IL8, SDC3, SDC4
  Endometrial cancer           1.64E-04   EGFR, ERBB2, GRB2, PIK3R1
  Non-small cell lung cancer   1.90E-04   EGFR, ERBB2, GRB2, PIK3R1
  Glioma                       3.90E-04   EGFR, IGF1R, GRB2, PIK3R1

KEGG, kyoto encyclopedia of genes and genomes.
